logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

BEKE-W (02423) spent US$2.9493 million to repurchase 541,500 shares on September 21.

date
19:46 22/09/2026
avatar
GMT Eight
BEKE-W (02423) announced that it spent US$2.9493 million to repurchase 541,500 shares on September 21, 2026.
BEKE-W (02423) announced that on September 21, 2026, it spent US$2.9493 million to repurchase 541,500 shares.
Related Articles
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.
HK Stock
SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.
China Stock
Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.
SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.
HK Stock
Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
China Stock
RECOMMEND
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.